The FDA on January 15, 2021 granted accelerated approval to DARZALEX Faspro® in combination with Bortezomib, Cyclophosphamide and Dexamethasone for newly diagnosed light chain (AL) Amyloidosis. DARZALEX FASPRO® is a product of Janssen Biotech Inc.
Bottom Ad
Advertisement
Subscribe
